

## Summer 2011

### In This Issue

American Society of Clinical Oncology (ASCO); American Association of Cancer Research (AACR), American Society of Ped. Hematology/Oncology (ASPHO), Society of Gynecologic Oncologists (SGO) Annual Meeting on Woman's Cancer, Oncology Nursing Society, Int. Conference on Malignant Lymphoma, and Others

### Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Hematological Cancer](#)
- [Leukemia,](#)
- [Myelodysplasia, and Transplantation](#)
- [Lung Cancer](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Sarcoma/Bone and Soft Tissue Cancers](#)
- [Other Cancer](#)

### NCI/CTEP Abstracts & Activities:

- [DCTD/DCP Abstracts](#)
- [DCTD and DCP Activities](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

### Research Highlights in this Issue:

**AALL0232:** The AALL0232 study for children with high-risk B-precursor acute lymphoblastic leukemia (ALL) compared high-dose (HD) methotrexate (MTX) with leucovorin rescue to Capizzi escalating MTX plus PEG asparaginase given during the interim maintenance phase of treatment. The results, which were presented at the ASCO 2011 Plenary Session, showed that 5-year event-free survival (EFS) for patients randomized to receive HD-MTX was significantly higher than for patients receiving Capizzi MTX (82 + 3.4% versus 75.4 + 3.6%, p=0.006). These results establish a new standard of care for children with high-risk B-precursor ALL.

**NCIC-MA.20:** MA.20 evaluated the addition of regional nodal irradiation (RNI) to whole breast irradiation (WBI) following breast conserving surgery (BCS) in women with high risk node-negative or node-positive breast cancer treated with BCS and adjuvant chemotherapy and/or endocrine therapy. A protocol specified interim analysis of relapse patterns, survival, and toxicity at 5 years demonstrated that additional RNI reduces the risk of loco-regional and distant recurrence and improves DFS with a trend in improved OS. The results of this study support the use of regional nodal irradiation in addition to WBI in women with early stage breast cancer at increased risk of recurrence.



## Cooperative Group Abstracts

### Breast Cancer

#### ACOSOG

Ellis MJ, Ding L, Shen D, Wallis J, Suman V, Luo J, Tao Y, Jeremy Hoog, Davies S, Lin L, Perou C, Tine BV, Bose R, Chang LW, Chen K, Ota D, Watson M, Wilson R, Hunt K, Mardis E: Analysis of luminal-type breast cancer by massively parallel sequencing. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. LB-87.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8af32ba1-289f-4f43-b9d3-9e44806821e1&cKey=bae82f3c-c765-4fc6-8c98-6d497d04704f&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}>

Protocol(s): ACOSOG-Z1031

#### ACRIN

Jolles P, Kostakoglu L, Bear H, Idowu M, Kurdziel K, Shankar L, Mankoff D, Duan F, L'Heureux D: Phase II Study of Fluorine-18 3'-Deoxy-3' Fluorothymidine (FLT) in Invasive Breast Cancer. J Clin Oncol 2011; 29(suppl): Abst. TPS125.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84250](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84250)

Protocol(s): 8029

Tromberg BJ, Butler JA, Mankoff DA, Isakoff SJ, Hylton NM, Yodh AG, Boas D, Paulsen K, Pogue BW, Kaufman PA, Mehta RS, Carpenter PM, Cerussi A, Zhang Z, Hartfeil DM, L'Heureux D: ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). J Clin Oncol 2011; 29(suppl): Abst. TPS249.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84074](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84074)

Protocol(s): ACRIN-6691

#### ECOG

Bell C, Maners A, Ziner KW, Champion VL: Understanding quality of life and healthcare priority needs during survivorship in younger breast cancer survivor. Oncol Nurs Forum 2011; 38(1): pg. A36.

<http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf>

Protocol(s): E2Z04

Schneider BP, Li L, Miller KD, Flockhart DA, Radovich B, Hancock BA, Kassem N, Foroudi T, Koller D, Badve SS, Li Z, Partridge AH, O'Neill A, Sparano JA, Dang C, Northfelt D, Smith ML, Railey E, Sledge GW: Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol 2011; 29(suppl): Abst. 1000.

[http://abstract.asco.org/AbstView\\_102\\_78499.html](http://abstract.asco.org/AbstView_102_78499.html)

Other Participant(s): CALGB

Protocol(s): E5103

Simpson JF, Sander ME, Page DL: Diagnostic Accuracy of Ductal Carcinoma In Situ: Results of Eastern Cooperative Oncology Trial 5194. United States and Canadian Academy of Pathology, San Antonio, TX, Feb 2011. Abst. 256.

[http://www.abstracts2view.com/uscap11/view.php?nu=USCAP11L\\_256](http://www.abstracts2view.com/uscap11/view.php?nu=USCAP11L_256)

Protocol(s): E5194

## NCCTG

Northfelt DW, Dueck AC, Flynn TP, Zander PJ, Stella PJ, Melnik M, Pavey ES, Perez EA: Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. J Clin Oncol 2011; 29(suppl): Abst. 1126.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77800](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77800)

Protocol(s): N0735

Perez EA, Dueck AC, Reinholz MM, Chen B, Geiger X, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, McCullough AE: Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 2011; 29(suppl): Abst. 10504.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79057](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79057)

Protocol(s): N9831

Reinholz MM, Dueck AC, Chen B, Geiger X, McCullough AE, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, Perez EA: Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 2011; 29(suppl): Abst. 10503.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81832](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81832)

Protocol(s): N9831

## NCIC Clinical Trials Group

Hershman DL, Cheung AM, Chapman JW, Ingle JN, Ahmed F, Hu H, Scher J, Leeson S, Elliott C, Le Maître A, Shepherd LE, Goss PE: Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study. J Clin Oncol 2011; 29(suppl): Abst. 518.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84625](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84625)

Protocol(s): NCIC-MA.27B

Parulekar W, Chen BE, Elliott C, Shepherd LE, Gelmon KA, Pritchard KI, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Lemieux J, Ganz PA, Stambolic V, Goodwin PJ: A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). J Clin Oncol 2011; 29(suppl): Abst. TPS103.

[http://origin.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82573](http://origin.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82573)

Protocol(s): NCIC-MA.32

Stearns V, Chapman JW, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maître A, Kundapur J, Shepherd LE, Goss PE: Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. J Clin Oncol 2011; 29(suppl): Abst. 525.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=78090](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78090)

Protocol(s): NCIC-MA.27

Whelan TJ, Olivotto I, Ackerman I, Chapman JW, Chua B, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Craighead P, Nolan MC, Bowen J, McCready DR, Pritchard KI, Levine MN, Parulekar W: NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. *J Clin Oncol* 2011; 29(suppl): Abst. LBA1003.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst\\_detail\\_view&confID=102&abstractID=79126](http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=79126)

Protocol(s): NCIC-MA.20

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Bramwell VH, Levine MN, Pritchard KI, Whelan TJ, Ingle JN, Parulekar W, Shepherd LE, Gelmon KA: Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. *J Clin Oncol* 2011; 29(suppl): Abst. 513.

[http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81808](http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81808)

Protocol(s): NCIC-MA.21, NCIC-MA.27

## NSABP

Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ: 25-hydroxy vitamin D and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP P-1. *J Clin Oncol* 2011; 29(suppl): Abst. 1528.

[http://abstract.asco.org/AbstView\\_102\\_76755.html](http://abstract.asco.org/AbstView_102_76755.html)

Protocol(s): NSABP-P-1

Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky A, Mehta RS, Fehrenbacher L, Pajon ER, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N: The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. *J Clin Oncol* 2011; 29(suppl): Abst. LBA1005.

[http://abstract.asco.org/AbstView\\_102\\_83942.html](http://abstract.asco.org/AbstView_102_83942.html)

Protocol(s): NSABP-B-40

Crager M, Tang G, Shak S: Using the 21-Gene Recurrence Score and the recently developed Recurrence Score-Pathologic-Clinical to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone. *J Clin Oncol* 2011; 29(suppl): Abst. 592.

[http://abstract.asco.org/AbstView\\_102\\_78110.html](http://abstract.asco.org/AbstView_102_78110.html)

Protocol(s): NSABP-B-14

Julian T, Costantino J, Vicini F, White J, Arthur D, Kuske R, Rabinovitch R, Winter K, Curran W, Wolmark N: Early Toxicity Results With 3D Conformal External Beam Therapy (CEBT) From the NSABP B-39 / RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. *J Clin Oncol* 2011; 29(suppl): Abst. 92.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst\\_detail\\_view&confID=100&abstractID=60277](http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=100&abstractID=60277)

Protocol(s): NSABP-B-39



Liu M, Wang L, Schaid DJ, Wickerham DL, Costantino JP, Goetz MP, Ames MM, Vogel VG, Paik S, Batzler A, Wolmark N, Nakamura Y, Kubo M, Kamatani N, Ingle JN, Weinshilboum RM: Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 4727.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=42a4e4de-967e-47ba-9ee1-e70c514a626c&cKey=102e3f1e-c54d-4194-a6e7-45b1992dde3c&mKey=%7b507D311A-B6EC-436A-BD67-6D14ED39622C%7d>

Protocol(s): NSABP-P-1, NSABP-P-2

## SWOG

Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart J, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregory BA, Flaherty LE, Livingston RB, Lew DL, Gralow J, Hortobagyi GN: First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. J Clin Oncol 2011; 29(suppl): Abst. 1004.

[http://abstract.asco.org/AbstView\\_102\\_74054.html](http://abstract.asco.org/AbstView_102_74054.html)

Other Participant(s): ECOG

Protocol(s): S0221

Gonzalez-Angulo AM, Barlow WE, Gralow JR, Meric-Bernstam F, Hayes DF, Moinpour CM, Ramsey SD, Schott A, Sparks D, Albain KS, Hortobagyi GN: SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. J Clin Oncol 2011; 29(suppl): Abst. TPS104.

[http://abstract.asco.org/AbstView\\_102\\_76547.html](http://abstract.asco.org/AbstView_102_76547.html)

Protocol(s): S1007

Ramsey SD, Barlow WE, Moinpour C, Gonzalez-Angulo AM, Hortobagyi GN, Veenstra DL, Garrison LP, Tunis SR, Baker LH: Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. J Clin Oncol 2011; 29(suppl): Abst. TPS101.

[http://abstract.asco.org/AbstView\\_102\\_82693.html](http://abstract.asco.org/AbstView_102_82693.html)

Protocol(s): S1007

Zirpoli GR, Brennan PM, Hong CC, McCann SC, Unger JM, Budd G, Hershman D, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi G, Gralow J, Albain K, Hayes D, Ambrosone C: Effect of physician recommendation on multivitamin and antioxidant supplement use during chemotherapy in an adjuvant trial for breast cancer (SWOG S0221). American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 4681.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=73b6a59d-cfe5-4b41-b6cc-bbc9f6572757&cKey=59dfd466-c618-420e-9bb8-11ba423d3e89&mKey=%7b507D311A-B6EC-436A-BD67-6D14ED39622C%7d>

Protocol(s): S0221

## CNS Cancer

### COG

Hummel TR: A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study. *J Clin Oncol* 2011; 29(suppl): Abst. 9579.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80733](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80733)

Protocol(s): ADVL0819

### NCCTG

Anderson SK, Lafky JM, Carrero XW, Kimlinger TK, Halling TM, Kumar S, Flynn PJ, Gross HM, Jaeckle KA, Buckner JC, Galanis E: Single nucleotides polymorphism (SNPs) and circulating endothelial cells (CECs) in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). *J Clin Oncol* 2011; 29(suppl): Abst. 2019.

[http://origin.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83751](http://origin.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83751)

Protocol(s): N0776

Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, Sarkaria JN, Scheithauer BW, Erickson BJ, Buckner JC: Phase I/II Trial of Sorafenib and Temsirolimus in Patients with Recurrent Glioblastoma. A North Central Cancer Treatment Group Study. *J Clin Oncol* 2011; 29(suppl): Abst. 2033.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80655](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80655)

Protocol(s): N0572

Sarkaria JN, Peller PJ, Galanis E, Jacobson MS, Wu W, Jaeckle KA, Buckner JC: FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K. *J Clin Oncol* 2011; 29(suppl): Abst. e12501.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84868](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84868)

Protocol(s): N057K

### RTOG

Aldape K, Wang M, Sulman E, Cahill D, Hegi M, Colman H, Jones G, Chakravarti A, Mehta M, Andrews D, Long L, Diefes K, Heathcock L, Jenkins R, Schultz C, Gilbert M: RTOG 0525: molecular correlates from randomized phase III trial of newly diagnosed glioblastoma (GBM). *J Clin Oncol* 2011; 29(suppl): Abst. LBA2000.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83983](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83983)

Protocol(s): RTOG-0525

Armstrong T, Wang M, Wefel J, Bottomley A, Mendoza T, Coens C, Werner-Wasik M, Brachman D, Choucair A, Gilbert M: Clinical Utility of Neurocognitive Function (NCF), Quality of Life (QOL) and Symptom Assessment as Prognostic Factors for Survival and Measures of Treatment Effects on RTOG 0525. *J Clin Oncol* 2011; 29(suppl): Abst. 2016.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79423](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79423)

Protocol(s): RTOG-0525

Gilbert M, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle K, Brown P, Armstrong T, Wefel J, Corn B, Mahajan A, Schultz C, Erridge S, Chakravarti A, Curran W, Mehta M: RTOG 0525: A Randomized Phase III Trial Comparing Standard Adjuvant Temozolomide (TMZ) With a Dose-Dense (dd) Schedule in Newly Diagnosed Glioblastoma (GBM). *J Clin Oncol* 2011; 29(suppl): Abst. 2006.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79659](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79659)

Protocol(s): RTOG-0525

Wang M, Dignam J, Won M, Curran W, Mehta M, Gilbert M: Variation Over Time and Inter-Dependence Between Disease Progression and Death Among Patients With Glioblastoma (GBM) on RTOG 0525. *J Clin Oncol* 2011; 29(suppl): Abst. 2017.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80549](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80549)

Protocol(s): RTOG-0525

## Gastrointestinal Cancer

### *ACRIN*

Wald C, Nalesnik M, Pomfret EA, Russo M, Rosen MA, Hartfeil DM, Fox P, Heckel ML, Gatsonis C: ACRIN 6690: Can contemporary imaging reduce false-positive rate in liver transplant (LT) allocation? A multicenter comparison of CT and MRI for diagnosis of hepatocellular carcinoma (HCC). *J Clin Oncol* 2011; 29(suppl): Abst. TPS177.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84325](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84325)

Protocol(s): ACRIN-6690

### *CALGB*

Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson RS, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Willett CG, Goldberg RM, Venook AP, Mayer RJ: Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101. *J Clin Oncol* 2011; 29(suppl): Abst. 4003.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82318](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82318)

Other Participant(s): NCCTG

Protocol(s): CALGB-80101

Nixon AB, Pang H, Starr MD, Hollis D, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI: Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. *J Clin Oncol* 2011; 29(suppl): Abst. 10508.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81814](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81814)

Protocol(s): CALGB-80303

Van Loon K, Wigler D, Niedzwiecki D, Hollis D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg R, Meyerhardt JA: Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients. *J Clin Oncol* 2011; 29(suppl): Abst. e14026.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83062](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83062)

Protocol(s): C80405, C89803

Venook AP, Niedzwiecki D, Lopatin M, Lee M, Friedman PN, Frankel W, Clark-Langone K, Yoshizawa C, Millward C, Shak S, Goldberg RM, Mahmoud N, Schilsky RL, Bertagnolli MM: Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581. J Clin Oncol 2011; 29(suppl): Abst. 3518.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77737](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77737)

Protocol(s): C9581

## NCCTG

Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG: Influence of KRAS and BRAF mutational status and rash on Disease-Free Survival (DFS) in resected stage III colon cancer patients receiving cetuximab (Cmab) – Results from NCCTG N0147. J Clin Oncol 2011; 29(suppl): Abst. 3607.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80710](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80710)

Protocol(s): N0147

Bleiberg H, Sargent DJ, GASTRIC: Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. J Clin Oncol 2011; 29(suppl): Abst. 4109.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83472](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83472)

Protocol(s): NCCTG-78-48-51, NCCTG-79-41-51, NCCTG-83-41-51

Foster NR, Sinicrope F, Yothers GA, Allegra CJ, Sargent DJ: Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. J Clin Oncol 2011; 29(suppl): Abst. 10590.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82287](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82287)

Protocol(s): N994C

Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ: Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841. J Clin Oncol 2011; 29(suppl): Abst. 3571.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79465](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79465)

Protocol(s): N0147, N9741, N9841

Grothey A, Heun JM, Branda M, Goldberg RM, Sargent DJ: New lesions vs growth of existing disease: does it impact prognosis? J Clin Oncol 2011; 29(suppl): Abst. 2579.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82873](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82873)

Protocol(s): N9741

Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Sinicrope F, Nair SG, Alberts SR: Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147. J Clin Oncol 2011; 29(suppl): Abst. 3522.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80808](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80808)

Protocol(s): N0147



Hubbard JM, Alberts SR, Loui WS, Mahoney MR, Roberts LR, Smyrk TC, Gatalica Z, Kumar S, Dakhil SR, Flynn PJ, Lafky JM, Bury MJ: Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745. *J Clin Oncol* 2011; 29(suppl): Abst. 4116.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84051](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84051)

Protocol(s): N0745

Kim GP, Foster NR, Salim M, Flynn PJ, Moore Jr. DF, Zon R, Mowat RB, McCullough A, Meyers JP, Alberts SR: Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma. *J Clin Oncol* 2011; 29(suppl 4): Abst. 238.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=103&abstractID=71370](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71370)

Protocol(s): N064B

Kim GP, Foster NR, Salim M, Flynn PJ, Moore Jr. DF, Zon R, Mowat RB, Wiesenfeld M, McCullough AE, Alberts SR: Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. *J Clin Oncol* 2011; 29(suppl): Abst. 4030.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82619](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82619)

Protocol(s): N064B

Lafky JM, Bot BM, Morlan BW, Anderson SK, Kimlinger TK, Halling TM, Kumar S, Reynolds JT, Stella PJ, Dakhil SR, Loui WS, Alberts SR, Grothey A: Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib. *J Clin Oncol* 2011; 29(suppl): Abst. e14063.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83471](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83471)

Protocol(s): N054C

Lafky JM, Bot BM, Morlan BW, Grothey A: Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 4131.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b3725d8a-a800-4cc4-b970-0930f769ec50&cKey=5ce30236-5aae-4e72-91be-6a073b1fa120&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}>

Protocol(s): N054C

Mahoney MR, Sloan JA, Hubbard JM, Liu H, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Nair SG, Sargent DJ, Alberts SR: Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. *J Clin Oncol* 2011; 29(suppl): Abst. 3541.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84660](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84660)

Protocol(s): N0147

Shi Q, Hubbard JM, Yothers GA, Andre T, Saltz L, Francini G, Bot BM, Twelves C, Buyse ME, Grothey A, Sargent DJ: Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. *J Clin Oncol* 2011; 29(suppl): Abst. 3556.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84534](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84534)

Protocol(s): N0441

Sinicrope F, Foster NR, Yothers GA, Benson AB, Haller DG, Seitz J, Labianca R, Benedetti J, Goldberg RM, Gramont AD, Sargent DJ: Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer – an analysis of the ACCENT database. J Clin Oncol 2011; 29(suppl): Abst. e21126.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83516](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83516)

Protocol(s): N0441

## *NSABP*

Allegra CJ, Yothers GA, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Wolmark N: Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer. J Clin Oncol 2011; 29(suppl): Abst. 3508.

[http://abstract.asco.org/AbstView\\_102\\_78086.html](http://abstract.asco.org/AbstView_102_78086.html)

Protocol(s): NSABP-C-08

Chapman JAW, O'Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ, for the ACCENT collaborative group: Comparison of innovative estimation of efficacy to standard using the ACCENT database. J Clin Oncol 2011; 29(suppl): Abst. 3616.

[http://abstract.asco.org/AbstView\\_102\\_78884.html](http://abstract.asco.org/AbstView_102_78884.html)

Other Participant(s): NCCTG

Protocol(s): N0441, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Van Cutsem E, Alberts SR, Yothers GA, Sargent DJ: Predictive and prognostic value of gender in early stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database. J Clin Oncol 2011; 29(suppl): Abst. 3619.

[http://abstract.asco.org/AbstView\\_102\\_79417.html](http://abstract.asco.org/AbstView_102_79417.html)

Other Participant(s): NCCTG

Protocol(s): N0441, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

Roh MS, Yothers G, O'Connell MJ, Beart, Jr RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, Landry JC, Ryan DP, Arora A, Evans TL, Soori GS, Chu L, Landes RV, Mohiuddin M, Lopa S, Wolmark N: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29(suppl): Abst. 3503.

[http://abstract.asco.org/AbstView\\_102\\_76910.html](http://abstract.asco.org/AbstView_102_76910.html)

Other Participant(s): NCCTG

Protocol(s): NSABP-R-04

## *RTOG*

Gunderson L, Winter K, Ajani J, Pedersen J, Benson A, Thomas C, Mayer R, Haddock M, Rich T, Willett C: Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. J Clin Oncol 2011; 29(suppl 4): Abst. 367.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=103&abstractID=70410](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70410)

Protocol(s): RTOG-98-11

Gunderson L, Winter K, Ajani J, Pedersen J, Benson A, Thomas C, Mayer R, Haddock M, Rich T, Willett C: Long-term Update of U.S. GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Disease-free and Overall Survival with 5FU-Mitomycin vs 5FU-Cisplatin. J Clin Oncol 2011; 29(suppl): Abst. 367.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=103&abstractID=70410](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70410)

Protocol(s): RTOG-98-11

Kachnic L, Winter K, Myerson R, Goodyear M, Willins J, Esthappen J, Haddock M, Rotman M, Parikh P, Willett C: Two-year Outcomes of RTOG 0529: A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal. J Clin Oncol 2011; 29(suppl 4): Abst. 368.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=103&abstractID=71101](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71101)

Protocol(s): RTOG-0529

Li D, Moughan J, Crane C, Hoffman J, Regine W, Abrams R, Safran H, Freedman G, Guha C, Abbruzzese J: Association of RecQ1 A159C polymorphism with overall survival of patients with resected pancreatic cancer: A replication study in RTOG 9704. J Clin Oncol 2011; 29(suppl 4): Abst. 156.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=103&abstractID=70619](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70619)

Protocol(s): RTOG-97-04

Tempero M, Winter K, Kim G, Kakar S, Hyun T, Regine W, Mowat R, Charpentier K, Small W, Guha C, Chang D, Biankin A: S100A2 as a Prognostic Marker in Patients Receiving Adjuvant Therapy for Pancreatic Cancer (PC): a Secondary Analysis of RTOG 9704. J Clin Oncol 2011; 29(suppl): Abst. 4118.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84182](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84182)

Protocol(s): RTOG-97-04

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman J, Okuno SH, Kane, III JM, von Mehren M, Eisenberg BL: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132. J Clin Oncol 2011; 29(suppl): Abst. 10057.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80887](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80887)

Protocol(s): RTOG-0132

Wong S, Moughan J, Meropol N, Anne P, Kachnic L, Rashid A, Watson J, Mitchell E, Pollock J, Lee R, Haddock M, Erickson B, Willett C: Efficacy Endpoints of RTOG 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine (C) and Irinotecan (I) or C and Oxaliplatin (O) With Concurrent Radiation Therapy (RT) for Locally Advanced Rectal Cancer. J Clin Oncol 2011; 29(suppl): Abst. 4021.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=55&abstractID=31098](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31098)

Protocol(s): RTOG-0247

## SWOG

Bohanes P, Goldman B, Benedetti J, Blanke C, Leichman L, Iqbal S, Thomas C, Corless C, Gold P, Lenz H: Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative study (SWOG 0356). *J Clin Oncol* 2011; 29(supp 4): Abst. 2.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=103&abstractID=71402](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71402)

Protocol(s): S0356

Bohanes PO, Goldman BH, Leichman LP, Blanke CD, Iqbal S, Thomas CR, Corless CL, Billingsley KG, Danenberg KD, Zhang W, Benedetti JK, Gold PJ, Lenz H: Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). *J Clin Oncol* 2011; 29(suppl): Abst. 4023.

[http://abstract.asco.org/AbstView\\_102\\_82045.html](http://abstract.asco.org/AbstView_102_82045.html)

Protocol(s): S0356

Wilson P, Bohanes P, Rankin C, Benedetti J, Ulrich C, Smalley S, Makar D, Zhang W, Winder T, Ning Y, Gerger A, Benhaim L, El-Khoueiry R, Labonte M, Blanke C, Lenz H: The final results of the SWOG S9304 phase III intergroup trial's pharmacogenetic analysis: Association of polymorphisms with survival and toxicity in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation (RT). *J Clin Oncol* 2011; 29(suppl): Abst. 3542.

[http://abstract.asco.org/AbstView\\_102\\_84455.html](http://abstract.asco.org/AbstView_102_84455.html)

Protocol(s): INT-0144

## Genitourinary Cancer

### COG

Mullen EA, Anderson JR, Steacy KJ, Geller JI, Green DM, Norkool P, Fernandez CV, Khanna G, Malogolowkin MH, Dome JS: The impact of surveillance imaging on overall survival in patients with recurrent Wilms tumor: A report from the Children's Oncology Group. *J Clin Oncol* 2011; 29(suppl): Abst. 9536.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82480](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82480)

Protocol(s): Q9401

Sharma R, Jasty R, Bruch SW, Kitchen BJ, Mody RJ, Chamdin A: A Report Of Renal Artery Embolization For Hematuria Facilitating Neoadjuvant Chemotherapy In An Unresectable Malignant Renal Rhabdoid Tumor. *Pediatr Blood Cancer* 2011; 56(6): pg. 967.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AREN0321

### ECOG

Bhatt RS, Manola J, Bullock AJ, Zhang L, Balzer-Haas NS, Pins MR, Atkins MB, DiPaola RS: Host-mediated changes in patients receiving antiangiogenic therapy for resected RCC. *J Clin Oncol* 2011; 29(suppl): Abst. 4557.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81790](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81790)

Protocol(s): E2805



Liu G, Chen Y, DiPaola RS, Carducci MA, Wilding G: Final results on phase II study of a weekly schedule of ixabepilone in patients with metastatic castrate-refractory prostate cancer (E3803): A trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2011; 29(suppl): Abst. 4529.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81673](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81673)

Protocol(s): E3803

## *NCIC Clinical Trials Group*

Crook JM, O'Callaghan CJ, Ding K, Duncan G, Dearnaley D, Higano C, Horwitz E, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Loque J, Schellhammer P, Saad F, Klotz L: A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). *J Clin Oncol* 2011; 29(suppl): Abst. 4514.

[http://abstract.asco.org/AbstView\\_102\\_77775.html](http://abstract.asco.org/AbstView_102_77775.html)

Other Participant(s): SWOG

Protocol(s): JPR.7

Klotz L, O'Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, Malone S, Goldenberg SL, Gospodarowicz MK, Crook JM: A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. *J Clin Oncol* 2011; 29(suppl 7): Abst. 3.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=104&abstractID=72503](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=104&abstractID=72503)

Other Participant(s): COG, SWOG

Protocol(s): JPR.7

## *RTOG*

Lee W, Dignam J, Bruner D, Efstathiou J, Yan Y, Hanks G, Roach M, Pilepich M, Sandler H: Does enrollment setting influence patient attributes and outcomes in RTOG prostate cancer trials? *J Clin Oncol* 2011; 29(suppl): Abst. 4607.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=78946](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78946)

Protocol(s): RTOG-85-31, RTOG-86-10, RTOG-92-02, RTOG-94-13

## *SWOG*

Parsons JK, Schenk J, Arnold K, Messer K, Till C, Thompson IM, Kristal A: Finasteride reduces the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. American Urological Association, Washington, DC, May 2011.

Protocol(s): SWOG-9217

## Gynecologic Cancer

### GOG

Atri M, Zhang Z, Marques H, Gorelick J, Harisinghani M, Sohaib A, Koh DM, Raman S, Gee M, Choi H, Gold M: Utility of preoperative ferumoxtran-10 enhanced MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. *J Clin Oncol* 2011; 29(suppl): Abst. 5035.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=74500](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74500)

Other Participant(s): ACRIN

Protocol(s): GOG-0233

Burger R, Brady M, Bookman M, Monk B, Walker J, Homesley H, Fowler J, Greer B, Boente M, Liang S: Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2011; 120(suppl 1): pg. S5, Abst. 7.

<http://www.sciencedirect.com/science/article/pii/S0090825810008978>

Protocol(s): GOG-0218

Chase D, Sill M, Chambers M, Darcy K, Han E, Fruehauf J, Monk B, Buening B, Sorosky J, Burger R: Changes in tumor blood flow as estimated by dynamic-contrast magnetic resonance imaging (DC-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPD) patients: exploratory analysis of a Gynecologic Oncolo. *Gynecologic Oncology* 2011; 120(suppl 1): pg. S65, Abst. 150.

<http://www.sciencedirect.com/science/article/pii/S0090825810010401>

Protocol(s): GOG-0170D

Dizon DS, Sill M, Gould NS, Rubin SC, Yamada SD, DeBernardo R, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM: Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921. *J Clin Oncol* 2011; 29(suppl): Abst. 5066.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=74267](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74267)

Protocol(s): GOG-9921

Fleming GF, Filiaci VL, Hanjani P, Burke II JJ, Davidson SA, Leslie KK, Zaino RJ: Hormonal therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. *J Clin Oncol* 2011; 29(suppl): Abst. 5014.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=74397](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74397)

Protocol(s): GOG-0248

Gold M, Landrum L, Mannel R, Chuang L, Yu J, McCourt C, Zhang Z, Marques H, Gorelick J, Atri M: MRI prior to systematic lymphadenectomy in patients with locally advanced cervical cancer. *J Clin Oncol* 2011; 29(suppl): Abst. 5042.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79146](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79146)

Protocol(s): GOG-0233

Hill EK, Brady WK, Birrer MJ, Darcy KM, McGuire WP, Hoskins WJ, Warshal DP, Drake R, Hanjani P, Hurteau JA: Cyclin D1 and p57 expression in advanced ovarian epithelial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2011; 29(suppl): Abst. 5086.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=85085](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=85085)

Protocol(s): GOG-111

Milam MR, Java J, Walker JL, Parker LP, Metzinger DS, Coleman RL: Incidence of nodal metastasis in endometrioid endometrial cancer risk groups: a Gynecologic Oncology Group multicenter review. *Gynecologic Oncology* 2011; 120(suppl 1): pg. S4, Abst. 5.

<http://www.sciencedirect.com/science/article/pii/S0090825810008954>

Protocol(s): GOG-LAP2

Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, Homesley HD, Walker JL: A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2011; 120(suppl 1): pg. S2, Abst. 1.

<http://www.sciencedirect.com/science/article/pii/S0090825810008917>

Protocol(s): GOG-0205

Moore KN, Sill M, Miller DS, Disilvestro P, De Geest K, Rose PG, Carnenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM: A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) in women with locally advanced cervical cancer (CXCA): a GOG study. *J Clin Oncol* 2011; 29(suppl): Abst. 5032.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84396](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84396)

Protocol(s): GOG-9918

Rungruang B, Miller A, Richard S, Hamilton C, Rodriguez N, Bookman M, Maxwell G, Krivak T, Horowitz N: Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease? A Gynecologic Oncology Group study. *Gynecologic Oncology* 2011; 120(suppl 1): pg. S13-14, Abst. 29.

<http://www.sciencedirect.com/science/article/pii/S0090825810009194>

Protocol(s): GOG-0182

Santin A, Griffin P, Sill M, McMeekin D, Leitao M, Brown J, Sutton G, Van Le L, Boardman C: Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2011; 120(suppl 1): pg. S18, Abst. 40.

<http://www.sciencedirect.com/science/article/pii/S0090825810009303>

Protocol(s): GOG-0227E

## Head and Neck Cancer

### ECOG

Psyrris D, Ghebremichael M, Pectasides E, Dimou A, Burtress BA, Rimm D, Wanebo HJ, Forastiere AA: p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). *J Clin Oncol* 2011; 29(suppl): Abst. e16032.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83432](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83432)

Protocol(s): E2303

## RTOG

Ang K, Zhang Q, Rosenthal D, Nguyen-Tân P, Sherman E, Weber R, Galvin J, Schwartz D, El-Naggar A, Gillison M, Jordan R, List M, Konski A, Thorstad W, Beitler J, Garden A, Spanos W, Trotti A, Yom S, Axelrod R: A Randomized Phase III Trial (RTOG 0522) of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III-IV Head and Neck Squamous Cell Carcinomas (HNC). *J Clin Oncol* 2011; 29(suppl): Abst. 5500.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79086](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79086)

Protocol(s): RTOG-0522

Lee N, Zhang Q, Garden A, Kim J, Pfister D, Mechalakos J, Hu K, Le Q, Glisson B, Chan A, Ang K: Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615. *J Clin Oncol* 2011; 29(suppl): Abst. 5516.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77744](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77744)

Protocol(s): RTOG-0615

## Leukemia, Myelodysplasia, and Transplantation

### COG

Albano EA, West KL, Dolan S, Neiman J, Kaiser NA, Rannie M, Chin J: The Financial Cost Of Central Line Associated Blood Stream Infections In Pediatric Acute Myeloid Leukemia. *Pediatr Blood Cancer* 2011; 56(6): pg. 942.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AAML0531

Brown PA, Kaeding A, Magoon D, Small D, Jones T, Devidas M, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hilden JM, Hunger SP: Identification of a safe and biologically active dose of the FLT3 inhibitor lestaurtinib in combination with chemotherapy in infants with MLL-rearranged (MLL-r) ALL: A Children's Oncology Group Study. *Pediatr Blood Cancer* 2011; 56(6): pg. 899.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AALL0631

Canner JA, Alonzo T, Franklin J, Freyer DR, Gamis AS, Gerbing RB, Lange BJ, Meshinchi S, Woods WG, Perentesis JP, Horan JT: Treatment outcomes in older adolescent and young adult (AYA) patients with newly diagnosed AML. *J Clin Oncol* 2011; 29(suppl): Abst. 9506.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84168](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84168)

Protocol(s): CCG-2961

Chen I, Harvey RC, Mullighan CG, Loh ML, Devidas M, Borowitz MJ, Tasian SK, Payne-Turner D, Wharton W, Pullen J, Carroll AJ, Carroll WL, Camitta BM, Hunger SP, Winick NJ, Willman CL: Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group. *J Clin Oncol* 2011; 29(suppl): Abst. 9505.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=85112](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=85112)

Protocol(s): POG-9905



De Angulo GR, Muthusami S, Fort JA, Pefkarou AC, Escalon EA, Khatib ZA: Coexpression Of Inversion 16 And Philadelphia Chromosome In A Patient With De Novo Acute Myelogenous Leukemia. *Pediatr Blood Cancer* 2011; 56(6): pg. 933.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AAML0531

Larsen EC, Salzer WL, Devidas M, Nachman JB, Raetz EA, Loh ML, Heerema NA, Carroll AJ, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger SP, Carroll WL: Comparison of highdose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. *J Clin Oncol* 2011; 29(suppl): Abst. 3.

[http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83893](http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83893)

Protocol(s): AALL0232

Levendoglu-Tugal O, Gimenez C, Humayun Islam K, Sandoval C, Ozkaynak MF, Hochberg JC: Minimal Residual Disease In Pediatric Leukemia Patients. *Pediatr Blood Cancer* 2011; 56(6): pg. 929.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): Multiple Trials

Lew G, Yanofsky RA, Winick NJ, Rheingold SR, Jorstad DT, Lu X, Devidas M, Whitlock JA, Hunger SP, Carroll WL: Intensive vincristine is not feasible in intermediate-risk relapse of childhood acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group study AALL0433. *Pediatr Blood Cancer* 2011; 56(6): pg. 919.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AALL0433

Maloney KW, Larsen EC, Mattano LA, Friedmann AM, Devidas M, Nachman JB, Raetz EA, Winick NJ, Whitlock JA, Hunger SP, Carroll WL: Improved toxic mortality rates for children with down syndrome acute lymphoblastic leukemia (DS-ALL) treated on Children's Oncology Group (COG) trials for standard risk (SR;AALL0331) but not high risk (HR;AALL0232) ALL. *Pediatr Blood Cancer* 2011; 56(6): pg. 900.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AALL0232

Rochowski A, Alonzo T, Gerbing RB, Lange BJ, Alter BP: Fanconi Anemia Patients With AML Have Different Cytogenetic Clones Than De Novo Cases. *Pediatr Blood Cancer* 2011; 56(6): pg. 921.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): CCG-2961

Salzer WL, Asselin BL, Supko J, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz EA, Carroll WL, Hunger SP: Administration Of Erwinia Asparaginase Following Allergy To PEG-Asparaginase In Children And Young Adults With Acute Lymphoblastic Leukemia Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From The Children's Oncology Group (COG). *Pediatr Blood Cancer* 2011; 56(6): pg. 922.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.23092/abstract>

Protocol(s): AALL07P2

Winick NJ, Salzer WL, Devidas M, Nachman JB, Raetz EA, Loh ML, Heerema NA, Carroll AJ, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Hunger SP, Carroll WL, Larsen EC: Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. *J Clin Oncol* 2011; 29(suppl): Abst. 9504.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83582](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83582)

Protocol(s): AALL0232

## SWOG

Michelson A, Kopecky KJ, Koegle E, Anderson JE, Godwin JE, Petersdorf SH, List AF, Willman CL, Appelbaum FR, Radich JP, Ganapathi M, Ganapathi R, Advani AS: Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes. *J Clin Oncol* 2011; 29(suppl): Abst. 6564.

[http://abstract.asco.org/AbstView\\_102\\_79396.html](http://abstract.asco.org/AbstView_102_79396.html)

Protocol(s): SWOG-9031, SWOG-9126, SWOG-9333, SWOG-9500

## Lung Cancer

### ACOSOG

Fernando HC, Landrenau RJ, Mandraker S, Hillman S, Nichols F, DiPetrillo TA, Heron DE, Meyers BF, Jones DR, Starnes S, Putnam JB: Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study. American Association for Thoracic Surgery, Philadelphia, PA, May 2011. Session 55.

<http://www.aats.org/annualmeeting/Abstracts/2011/55.html>

Protocol(s): ACOSOG-Z4032

### ACRIN

Marcus, P: Recruitment methods employed during the National Lung Screening Trial. Society for Clinical Trials, Vancouver, BC, May 2011. Session 1C, Abst. 17.

<http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf>

Protocol(s): ACRIN-6654

### CALGB

Salama JK, Hodgson LD, Pang H, Green MR, Urbanic JJ, Blackstock AW, Crawford J, Bogart JA, Vokes EE: Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with concurrent chemotherapy and high dose (70 Gy) daily radiotherapy, a pooled analysis of three CALGB studies. *J Clin Oncol* 2011; 29(suppl): Abst. 7078.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=78904](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78904)

Protocol(s): CALGB-30002, CALGB-30206, CALGB-39808

Strauss GM, Wang XF, Maddaus M, Johnstone D, Johnson E, Harpole D, Gillenwater HH, Gu L, Sugarbaker D, Green MR, Graziano SL, Kratzke RA, Schilsky RL, Crawford J, Vokes EE: Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. *J Clin Oncol* 2011; 29(suppl): Abst. 7015.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80550](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80550)

Protocol(s): CALGB-9633

## ECOG

Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano SL, Adjei AA, Schiller J: Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29(suppl): Abst. 7013.

[http://abstract.asco.org/AbstView\\_102\\_81235.html](http://abstract.asco.org/AbstView_102_81235.html)

Other Participant(s): CALGB, NCCTG, SWOG

Protocol(s): E1505

## NCCTG

Mandrekar SJ, Qi Y, Allen-Ziegler K, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA: Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. J Clin Oncol 2011; 29(suppl): Abst. 7005.

[http://abstract.asco.org/AbstView\\_102\\_81867.html](http://abstract.asco.org/AbstView_102_81867.html)

Other Participant(s): SWOG

Protocol(s): Multiple Trials, N0424

Molina JR, Dy GK, Foster NR, Ziegler KLA, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA: A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study. J Clin Oncol 2011; 29(suppl): Abst. 7513.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84434](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84434)

Protocol(s): N0626

Schild SE, Foster NR, Meyers JP, Olivier KR, Ross HJ, Molina JR, Stella PJ, Past LR, Garces YI, Adjei AA: Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): findings from a meta-analysis performed by the north central cancer treatment group (NCCTG). J Clin Oncol 2011; 29(suppl): Abst. 7074.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79299](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79299)

Protocol(s): NCCTG-86-20-51, NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-95-20-53

## NCIC Clinical Trials Group

Michiels S, Mauguen A, Fisher D, Burdett S, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Pechoux CL, Pignon J: Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. J Clin Oncol 2011; 29(suppl): Abst. 7004.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83123](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83123)

Other Participant(s): CALGB, ECOG, NCCTG, RTOG, SWOG

Protocol(s): Multiple Trials

## RTOG

Gondi V, Paulus R, Bruner D, Meyers C, Gore E, Wolfson A, Werner-Wasik M, Choy H, Movsas B: Prognostic Significance of QOL Deterioration During Early Lung Cancer Survivorship: Secondary Analysis of RTOG 0212 and 0214. *J Clin Oncol* 2011; 29(suppl): Abst. 6061.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77622](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77622)

Protocol(s): RTOG-0212, RTOG-0214

## SWOG

Chen Y, Moon J, Pandya KJ, Kelly K, Gaspar LE, Lau DHM, Hirsch FR, Gandara D: Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). *J Clin Oncol* 2011; 29(suppl): Abst. 7040.

[http://abstract.asco.org/AbstView\\_102\\_83663.html](http://abstract.asco.org/AbstView_102_83663.html)

Protocol(s): S0429

## Lymphoma and Plasma Cell Disorders

### CALGB

Dunleavy K, Pittalugal S, Wayne AS, Shovlin M, Johnson JL, Little R, Steinberg S, Cheson BD, Hsi E, Jaffe ES, Wilson WH: MYC+ aggressive-b-cell lymphomas: novel therapy of untreated burkitt lymphoma (bl) and MYC + diffuse large b-cell lymphoma (dlbcl) with da-epoch-r. *Annals of Oncology* (Oxford University Press) 2011; 22(suppl 4): pg. iv106, Abst. 071.

[http://annonc.oxfordjournals.org/content/22/suppl\\_4/iv106.short](http://annonc.oxfordjournals.org/content/22/suppl_4/iv106.short)

Protocol(s): CALGB-50103

Morrison VA, Jung SH, Johnson J, Leonard JP, Cheson BD: A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). *J Clin Oncol* 2011; 29(suppl): Abst. 8106.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=74&abstractID=47551](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=47551)

Protocol(s): CALGB-50501

Morrison VA, Jung SH, Johnson J, Leonard JP, Cheson BD: Therapy with bortezomib + lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501. *Annals of Oncology* (Oxford University Press) 2011; 22(suppl 4): pg. iv221, Abst. 436.

[http://annonc.oxfordjournals.org/content/22/suppl\\_4/iv220.short](http://annonc.oxfordjournals.org/content/22/suppl_4/iv220.short)

Protocol(s): CALGB-50501

### ECOG

Smith MR, Li H, Gordon LI, Gascoyne RD, Palletta EM, Forero-Torres A, Kahl BS, Advani RH, Horning SJ: Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma (MCL); 5 year follow-up of Eastern Cooperative Oncology group E1499. *Annals of Oncology* (Oxford University Press) 2011; 22(suppl 4): pg. iv86, Abst. 017.

[http://annonc.oxfordjournals.org/content/22/suppl\\_4/iv86.short](http://annonc.oxfordjournals.org/content/22/suppl_4/iv86.short)

Protocol(s): E1499



Winter JN, Hong F, Rimsza LM, LeBlanc ML, Variakojis D, Krajewska M, Haberman TM, Melnick AM, Weick JK, Reed JC, Fisher RI, Kahl BS, Gascoyne RD: Gene expression profiling using paraffin-embedded tissues and the nuclease protection assay in diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: An ECOG and SWOG correlative study of E4494. *Annals of Oncology* (Oxford University Press) 2011; 22(suppl 4): pg. iv149, Abst. 194.

[http://annonc.oxfordjournals.org/content/22/suppl\\_4/iv148.full.pdf+html](http://annonc.oxfordjournals.org/content/22/suppl_4/iv148.full.pdf+html)

Other Participant(s): SWOG

Protocol(s): E4494

## SWOG

Mahadevan D, Unger JM, Persky DO, Spier C, Young F, LeBlanc M, Fisher RI, Miller TP: Phase II trial of cisplatin plus etoposide plus Gemcitabine plus solumedrol (PEGS) in Peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). *Annals of Oncology* (Oxford University Press) 2011; 22(suppl 4): pg. iv119, Abst. 112.

[http://annonc.oxfordjournals.org/content/22/suppl\\_4/iv119.short](http://annonc.oxfordjournals.org/content/22/suppl_4/iv119.short)

Protocol(s): S0350

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Shea T, Winter JN, Miller TP, Tubbs RR, Marcellus DC, Friedberg JW, Barton K, Mills G, LeBlanc M, Rimsza L, Forman SJ, Fisher RI: Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). *J Clin Oncol* 2011; 29(suppl): Abst. 8001.

[http://abstract.asco.org/AbstView\\_102\\_77208.html](http://abstract.asco.org/AbstView_102_77208.html)

Other Participant(s): ECOG

Protocol(s): S9704

## Melanoma/Skin Cancers

### ECOG

Agarwala SS, Lee S, Flaherty LE, Smylie MG, Kefford RF, Carson WE, Cohen GI, Kirkwood J: Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E1697). *J Clin Oncol* 2011; 29(suppl): Abst. 8505.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77947](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77947)

Protocol(s): E1697

### NCCTG

Kottschade LA, Suman V, Perez DG, McWilliams RR, Kaur JS, Amatruda T, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic S: A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or Nab-paclitaxel (ABI-007)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma (N0775): A North Central Cancer Treatment Group Study. *J Clin Oncol* 2011; 29(suppl): Abst. 8532.

[http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77235](http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77235)

Protocol(s): N0775

## Other Cancer

### COG

Baruchel S, Wu B, Mokhtari RB, Glade Bender JL, DuBois SG, Widemann BC, Park JR, Stempak D, Ahern CH, Weigel BJ: Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. *J Clin Oncol* 2011; 29(suppl): Abst. 9502.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=76045](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76045)

Protocol(s): ADVL0413, ADVL0613, ADVL0714, ADVL0815

Cherven BO, Docherty S, Donovan M, Hendricks-Ferguson VL, Roll LJ, Stegenga K, Haase JE: Multi-Institutional Behavioral Intervention: Experiences of the Site's Principal Investigators and Project Managers. *Oncol Nurs Forum* 2011; 38(2): pg. A87.

<http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf>

Protocol(s): ANUR0631

Docherty S, Robb SL, Haase JE, Phillips-Salimi C, Cherven BO, Stegenga K, Hendricks-Ferguson VL, Roll LJ: Parental Perceptions of Helpfulness and Meaningfulness of a Therapeutic Music Video Intervention for Adolescents and Young Adults Undergoing Stem Cell Transplantation. *Oncol Nurs Forum* 2011; 38(1): pg. A12.

<http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf>

Protocol(s): ANUR0631

Fouladi M, Perentesis JP, Wagner LM, Ingle AM, Gammon J, Thomas G, Krueger DA, Houghton P, Vinks S, Weigel BJ, Blaney S: A phase I trial of IMC-A12 and temsirolimus in children with refractory solid tumors: A Children's Oncology Group Study. *J Clin Oncol* 2011; 29(suppl): Abst. 9520.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83577](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83577)

Protocol(s): ADVL0813

Glade Bender JL, Lee A, Adamson PC, Ingle AM, Ahern CH, Wu B, Baruchel S, Harris PJ, Ames MM, Weigel BJ, Blaney SM: Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial. *J Clin Oncol* 2011; 29(suppl): Abst. 9501.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81126](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81126)

Protocol(s): ADVL0815

Haase JE, Robb SL, Fort AN: Powerful Messages Communicated through Music Videos by Adolescents/Young Adults Undergoing Stem Cell Transplant. *Oncol Nurs Forum* 2011; 38(2): pg. A12.

<http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf>

Protocol(s): ANUR0631

Hendricks-Ferguson VL, Cherven BO, Burns DS, Docherty S, Phillips-Salimi C, Roll LJ, Stegenga K, Haase JE, Donovan M: Issues in Adolescent and Young Adult Recruitment and Participation: Strategies and Outcomes from the Stories and Music for Adolescent Resilience during Transplant Clinical Trial. *Oncol Nurs Forum* 2011; 38(1): pg. A23.

<http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf>

Protocol(s): ANUR0631

Landier W, Knight KR, Wong FL, Lee JK, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Bhatia S, Gurney JG: Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales: A report from the Children's Oncology Group (COG). *J Clin Oncol* 2011; 29(suppl): Abst. 9515.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=75114](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=75114)

Protocol(s): A3973

Morozova O, Birol I, Corbett R, Mungall K, Attiyeh EF, Asgharzadeh S, Zhao Y, Moore RA, Hirst M, Jones S, Hogarty MD, Diskin SJ, Mosse YP, Diamond M, Sposto R, Ji L, Gerhard D, Smith MA, Khan J, Seeger RC, Marra MA, Maris JM: Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 926.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e23b3dc0-d3c6-449e-97e6-bdd4ac7a9416&cKey=7e42f201-b87c-44e1-9e08-f96689236d5b&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}>

Protocol(s): ANBL00B1, ANBL06B1

Muscal J, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern R, Reid JM, Ames MM, Weigel BJ, Blaney SM: A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study. *J Clin Oncol* 2011; 29(suppl): Abst. 9522.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=73830](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=73830)

Protocol(s): ADVL0916

Norris MD, Henderson M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming C, Fletcher J, Gherardi S, Kwek C, Russell AJ, London WB, Buxton AB, Ashton L, Sartorelli AC, Cohn SL, Schwab M, Marshall G, Perini G, Haber M: ABCC/MRP multidrug transporters contribute to neuroblastoma biology, pathogenesis and clinical outcome, independently of any role in cytotoxic drug efflux. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 954.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1e9d7bf3-0e72-41b4-9497-4c6c2571e994&cKey=5ec25177-fba1-442c-a4db-855aa371639d&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}>

Protocol(s): POG-9047

Pugh TJ, Lawrence M, Sougnez C, Getz G, Attiyeh EF, Hogarty MD, Diskin SJ, Mosse YP, Diamond M, Asgharzadeh S, Sposto R, Wei JS, Badgett TC, London WB, Gastier-Foster JM, Smith MA, Gerhard D, Seeger RC, Khan J, Meyerson M, Maris JM: Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 4756.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b6998c29-6e3f-495f-8544-698de95f915b&cKey=9e9c498f-2e6e-4673-83d2-be1752f02835&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}>

Protocol(s): ANBL00B1, ANBL06B1

## ECOG

Chang VT, Zhao F, Wagner LI, Sanford SD, Salsman JM, Fisch MJ: Symptom burden and change among adolescent/young adult (AYA) patients with breast, lung, colorectal, or prostate cancer. *J Clin Oncol* 2011; 29(suppl): Abst. 9064.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81011](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81011)

Protocol(s): E2Z02

Fisch MJ, Lee J, Weiss M, Wagner LI, Chang VT, Cella D, Manola J, Minasian LM, McCaskill-Stevens WJ, Mendoza TR, Cleeland CS: Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. *J Clin Oncol* 2011; 29(suppl): Abst. 6008.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77126](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77126)

Protocol(s): E2Z02

Rich TA, Manola J, Cella D, Cruciani RA, Fisch MJ: An evaluation of serum cytokine levels and fatigue and depression in ECOG E4Z02. *J Clin Oncol* 2011; 29(suppl): Abst. 9046.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=79783](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79783)

Protocol(s): E4Z02

Wagner LI, Zickl L, Smith ML, Cella D, Coles C, Patrick-Miller LJ, Manola J, Fisch MJ: Prospective assessment of symptom burden among cancer survivors with common solid tumors: Results from ECOG trial E2Z02. *J Clin Oncol* 2011; 29(suppl): Abst. 9137.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=82706](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82706)

Protocol(s): E2Z02

Weiss M, Manola J, Thompson MA, Thomas ML, Fisch MJ: A prospective, observational study of medication use among outpatients with common solid tumors. *J Clin Oncol* 2011; 29(suppl): Abst. 9055.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=80175](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80175)

Protocol(s): E2Z02

## NCCTG

Dueck AC, Sargent DJ, Novotny PJ, Decker PA, Nelson H, Qin R, Sloan JA: Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. *J Clin Oncol* 2011; 29(suppl): Abst. 6130.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=85098](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=85098)

Protocol(s): Multiple Trials

Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL: The evaluation of flaxseed for hot flashes, results of a randomized, controlled trial, NCCTG study N08C7. *J Clin Oncol* 2011; 29(suppl): Abst. CRA9015.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77648](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77648)

Protocol(s): NCCTG-N08C7

Reeves B, Dakhil SR, Sloan JA, Burger KN, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Lachance DH, Loprinzi; CL: Paclitaxel-associated acute pain syndrome (P-APS) and its association on the development of peripheral neuropathy: NCCTG trial N08C1. *J Clin Oncol* 2011; 29(suppl): Abst. 9047.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=76731](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76731)

Protocol(s): NCCTG-N08C1

Sloan JA, Mahoney MR, Sargent DJ, Hubbard JM, Liu H, Basch EM, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Alberts SR: Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from north central cancer treatment group (NCCTG) phase III trial N0147. *J Clin Oncol* 2011; 29(suppl): Abst. 6122.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84505](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84505)

Protocol(s): N0147

## RTOG

Wang M, Dignam J: The Impact of Association Between Endpoints on Performance in Seamless Phase II/III Clinical Trial Designs. Society for Clinical Trials, Vancouver, BC, May 2011. Session 4D, Abst. 91.

<http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf>

Protocol(s): Multiple Trials

Zhang Q, Freidlin B, Korn E, Dignam J: Comparison of Futility Monitoring Methods Using RTOG Clinical Trials. Society for Clinical Trials, Vancouver, BC, May 2011. Session 3E, Abst. 68.

<http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf>

Protocol(s): Multiple Trials

## SWOG

Anderson K, Hartline J, Harris-Talley J: Study transition from local in-person follow-up to centralized follow-up by mail. American Society of Preventive Oncology Annual Meeting (ASPO), Las Vegas, NV, Mar 2011.

Protocol(s): S0000

Cassano PA, Guertin KA, Kristal AR, Arnold KB, Crowley JJ, Hartline JA, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Klein E: Effect Of Vitamin E And Selenium On Rate Of Decline In FEV1: The Respiratory Ancillary Study To The Selenium And Vitamin E Cancer Prevention Trial (SELECT). *Am J of Respiratory and Critical Care Medicine* 2011; 183(): Abst. A6419.

[http://ajrccm.atsjournals.org/cgi/content/citation/183/1\\_MeetingAbstracts/A6419](http://ajrccm.atsjournals.org/cgi/content/citation/183/1_MeetingAbstracts/A6419)

Protocol(s): S0000

Guertin KA, Grant RK, Kristal AR, Arnold KB, Crowley JJ, Hartline JA, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Klein E, Cassano PA: Effect of vitamin E and selenium on F2-isoprostanes, a biomarker of oxidative stress. North American Congress of Epidemiology, Montreal, QC, Jun 2011. Abst. L30.

<http://www.epicongress2011.org/prelimprog.pdf>

Protocol(s): S0000

Hartline J, Smith A, Anderson K: A secure website for participant submission of follow-up data. Society for Clinical Trials, Vancouver, BC, May 2011. Session 1A, Abst. 03.

<http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf>

Protocol(s): S0000

Yee M, Hartline JA, Anderson, K: The consent process for transitioning a large trial to centralized follow-up. American Society of Preventive Oncology Annual Meeting (ASPO), Las Vegas, NV, Mar 2011.

Protocol(s): S0000



## Sarcoma/Bone and Soft Tissue Cancers

### COG

Mascarenhas L, Felgenhauer JL, Bond MC, Womer RB, Femino JD, Laack NN, Ranganathan S, Meyer J, Krailo M, Marina NM: Pilot study of adding vincristine, topotecan and cyclophosphamide to interval compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma family of tumors- A Children's Oncology Group trial. J Clin Oncol 2011; 29(suppl): Abst. 9526.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=84838](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84838)

Protocol(s): AEWS07P1

Tilan JU, Mtaweh H, Everhart LM, Long J, Barkauskas DA, Krailo M, Jeha D, Toretsky JA, Kitlinska J: Systemic levels of neuropeptide Y are elevated in Ewing's sarcoma patients. American Association of Cancer Research (AACR), Orlando, FL, Apr 2011. Abst. 4352.

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2734&sKey=41ccc4bb-caa2-42a9-88a6-564221f1d892&cKey=70177852-eae8-41a5-bfd2-14d894fa0fba&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}>

Protocol(s): AEWS0031

Walterhouse DO, Pappo AS, Meza J, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Meyer WH, Hawkins DS: Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). J Clin Oncol 2011; 29(suppl): Abst. 9516.

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=77259](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77259)

Protocol(s): ARST0331

## NCI/CTEP Abstracts & Activities

### Abstracts with DCTD and DCP Investigators

DiPiazza K, Souhan E, Finnigan S, Denicoff A, Friedman S, Montello M, Mooney MM, Schettino P, Zwiebel JA, Doroshov JH, Abrams JS: The Cancer Therapy Evaluation Program's (CTEP) implementation of the Operational Efficiency Working Group (OEWG) recommendations. J Clin Oncol 2011; 29(suppl): Abst. 6113.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83906](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83906)

Grubbs SS, Go RS, Berger MZ, Gonzalez M, Thompson MA, Enos R, Germain DCS, Denicoff A, Servididio C, Bearden JD, Zaren H, Wilkinson K, Krasna M, McCaskill-Stevens W, Bell M, Freeman RK, Miesfeldt S, Ravikumar TS, Nair SG, Bashey A: Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). J Clin Oncol 2011; 29(suppl): Abst. 6110.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=83703](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83703)

Kohn EC, Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, Kotz HL, Squires J, Houston ND, Chen HX, Wright JJ: A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. *J Clin Oncol* 2011; 29(suppl): Abst. 5019.

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81085](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81085)

## DCTD and DCP Activities

### *Educational*

Denicoff, A: Why Isn't Cancer Research More Successful?: Oncologists and their Teams Creating a Culture of Clinical Trials for the 'Next-Gen' System. *J Clin Oncol* 2011; 29(suppl): Special Session.

Zujewski, JA (DCTD/CTEP): Clinical Trial Design and Methodology. ASCO International Clinical Trials Workshop, Cairo, Egypt, Jan 2011.

### *Other*

Zujewski, JA (DCTD/CTEP): Focus On Health: Breast Cancer Awareness and Molecular Targets in the Pipeline for Breast Cancer. US State Department - Breast Cancer Awareness, Karachi, Islamabad, Pakistan, Jan 2011.

Zujewski, JA (DCTD/CTEP): Regulatory Issues - International perspective. ASCO International Clinical Trials Workshop, Cairo, Egypt, Jan 2011.

Zujewski, JA (DCTD/CTEP): Coordinated meeting on next generation trials of HER-2 positive breast cancer with the goal of addressing key questions regarding the resistance to HER2 targeting, discussing HER2-targeted drugs (including new agents), discussing other drugable targets in HER2-positive breast cancer, and recommending directions for future clinical trials in the treatment of HER2-positive breast cancer. Breast Cancer Steering Committee, Clinical Trials Planning Meeting, Rockville, MD, May 2011.

### *Scientific*

Abrams, J (DCTD/CTEP): Issues For Future Trials: Impact of Cooperative Group Reorganizations and Considerations for Future Trial Planning. Breast Cancer Steering Committee, Clinical Trials Planning Meeting, Rockville, MD, May 2011.

Zujewski, JA (DCTD/CTEP): Perspectives of Sponsors: Academic, Government, Cooperative Group. ASCO International Clinical Trials Workshop, Cairo, Egypt, Jan 2011.

Zujewski, JA and Gafur-Akhunov, MA (DCTD/CTEP): Epidemiology, Risks, Prevention: 'Global Burden of Breast Cancer', 'Breast Cancer Registry US and Uzbekistan', and 'Breast Cancer Risks and assessment tools'. Breast Cancer State of the Science, Tashkent, Uzbekistan, May 2011.

Zujewski, JA (DCTD/CTEP): Diagnosis, Staging, and Pathology: 'Breast Health Global Initiative', 'Breast Cancer Biology', and 'Education and Awareness'. Breast Cancer State of the Science, Tashkent, Uzbekistan, May 2011.

Zujewski, JA and Shakhnoza, NR (DCTD/CTEP): Cancer Treatment: 'Metastatic disease -systemic therapy', 'Supportive Care', and 'Patient "navigation"'. Breast Cancer State of the Science, Tashkent, Uzbekistan, May 2011.

Zujewski, JA (DCTD/CTEP): Clinical: 'Overview-palliative care', 'Clinical Trial Basics', and 'Components and Examples of (Breast Cancer) Clinical Trials'. Breast Cancer State of the Science, Tashkent, Uzbekistan, May 2011.

Zujewski, JA (DCTD/CTEP): Clinical trials experience in her2-positive breast cancer – lessons learned and current portfolio: Prior and current phase 3 studies: North American. Breast Cancer Steering Committee, Clinical Trials Planning Meeting, Rockville, MD, May 2011.

***Disclaimer:** References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.*